- Country: USA
- Summary: INTERCEPT® Platelet Processing Set with Dual Storage Containers
- UST Ref No: 116620750
- Deadline: 31 Mar 2025
- Financier: Self Financed
- Purchaser Ownership: Government
- Tender Value: Refer Document
- Notice Type: Tender
- Document Ref. No.: 25-005138
- Purchaser's Detail:Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details.
- Description:
- Description
INTERCEPT® Platelet Processing Set with Dual Storage Containers
Product Service Code: 6640 NAICS Code: 334516 Place of Performance: Bethesda, MDPOTS: 25-005138
Description
This is a notice of intent, not a request for a quotation. A solicitation document will not be issued, and quotations will not be requested.
The National Institutes of Health (NIH), Office of Purchasing and Contracts, on behalf of the Department of Transfusion Medicine (DTM), intends to award a firm fixed price contract on a sole-source basis to Cerus Corporation, located at 1220 Concord AVE STE 600 Concord, California 94520-4906, for a five (5) month base year of INTERCEPT® Platelet Processing Set with Dual Storage Containers (INT2540B). The period of performance will be from 04/01/2025 to 09/30/2025.
The Department of Transfusion Medicine currently utilizes the Cerus INTERCEPT® Technology to process platelets in the Transfusion Service Laboratory. This process reduces the potential of virus replication by ensuring that the transfused platelets are safe for patient use. The INTERCEPT® Platelet Processing Set with Dual Storage Containers are proprietary products and must be used with the existing equipment. The INTERCEPT® Blood System, is a registered trademark of the Cerus Corporation. As outlined in the Standard Operating Procedures of the Department of Transfusion Medicine, any of the following, materials, supplies, equipment, and services that impact the quality of products or services are considered critical. Specific characteristics must be controlled to guarantee the safety and quality of the outcome. The Cerus Corporation meets all the Department of Transfusion Medicine requirements, and compliance with the following:
• FDA 21 CFR 211: Current Good Manufacturing Practice for Finished Pharmaceuticals
• FDA 21 CFR 606: Current Good Manufacturing Practice for Blood and Blood Components
• FDA 21 CFR 820: Quality System Regulation
• FDA 21 CF... - Documents:
If you are registered member, kindly login to view full details of this tender notice:
CLICK HERE TO LOGININTERCEPT® Platelet Processing Set with Dual Storage Containers - USA Tender
The HEALTH AND HUMAN SERVICES, DEPARTMENT OF | NATIONAL INSTITUTES OF HEALTH, a Government sector organization in USA, has announced a new tender for INTERCEPT® Platelet Processing Set with Dual Storage Containers. This tender is published on USARFP under UST Ref No: 116620750 and is categorized as a Tender. Interested and eligible suppliers are invited to participate by reviewing the tender documents and submitting their bids before the deadline on 2025-03-31.
The estimated tender value is Refer Document, and full details, including technical specifications and submission requirements, are provided in the official tender documents. Ensure all submissions meet the criteria outlined to be considered for evaluation.
